Washington to receive $1.2 million in Medicaid reimbursement by Novartis
Washington has reached an agreement with Novartis Pharmaceuticals Corporation in its kickback scheme in order to promote its drug, Exjade. Attorney General Bob Ferguson said that the agreement forms to be part of a pending execution by the company.
The company would provide the state with $1.2 million in the form of Medicaid reimbursement. Ferguson said, “I will not tolerate schemes that put profits before patients. My office is committed to cracking down on those who endanger patients for the sake their bottom line”.
Novartis has paid kickbacks to the three large national specialty pharmacies- BioScrip, Accredo, and US Bioservices between 2007 and 2012. The companies were paid to show that the side effects will increase if the drug’s use is decline and also to lower the negative things about Exjade.
In federal filings, the company has agreed with many such things. The company will be paying $390 million to the federal government and the states. Washington is one of 11 states, which has sued the company and its share is $1.2 million.
Two of the pharmacies, BioScrip and Accredo Health Group, have agreed to pay $15 million and $60 million to settle the claims against them. In 2005, Exjade received green signal from the FDA to act as a treatment of chronic iron overload owing to blood transfusions.
Novartis then came up with the network of three national pharmacies called EPASS (Exjade Patient Assistance and Support Services). After a whistleblower claim, investigation against the company was started.
The overall ‘asthma epidemic’ among children has...Read More
People in huge numbers gathered in the Mount Lofty...Read More
As New Year is approaching, people have already...Read More
Alzheimer’s disease, the commonest cause of...Read More
Cases of opioid abuse have been increasing and...Read More
In an announcement made on December 22, cable giant...Read More